U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07843264) titled 'PPI Dosing Per CYP2C19 Genotype' on Sept. 11.
Brief Summary: This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Gastroesophageal Reflux Disease With Esophagitis
Intervention:
DRUG: CYP2C19 based dosing Proton Pump Inhibitors
Pantoprazole dosing based on CYP2C19 phenotypes
DRUG: Conventional proton pump inhibitor dose
conventional PPI dose of Pantoprazole 40 mg once or twice da...